Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease

Journal of Clinical Biochemistry and Nutrition

Volumn 48, Issue 2, 2011, Pages 112-116

  Tanida, Satoshi ^a   Mizoshita, Tsutomu ^a   Mizushima, Takashi ^a   Sasaki, Makoto ^b   Shimura, Takaya ^a   Kamiya, Takeshi ^a   Kataoka, Hiromi ^a   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IBD; MAdCAM 1; Oxidative stress; ROS

Indexed keywords

ALPHA4BETA7 INTEGRIN; GLYCOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CELL INFILTRATION; ENDOTHELIUM CELL; ENTERITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; LAMINA PROPRIA; LYMPHOCYTE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 79952433233     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.10-41     Document Type: Review

References (69)

1. Hoffmann JC, Pawlowski NN, Kühl AA, Höhne W, Zeitz M. Animal models of inflammatory bowel disease: an overview. Pathobiology 2002; 70: 121-130.
2. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-1828.
3. Ohyashiki T, Ohtsuka T, Mohri T. A change in the lipid fluidity of the porcine intestinal brush-border membranes by lipid peroxidation. Studies using pyrene and fluorescent stearic acid derivatives. Biochim Biophys Acta 1986; 861: 311-318.
4. Jourd'Heuil D, Vaananen P, Meddings JB. Lipid peroxidation of the brush-border membrane: membrane physical properties and glucose transport. Am J Physiol 1993; 264: G1009-G1015. (Pubitemid 23196802)
5. Riedle B, Kerjaschk D. Reactive oxygen species cause direct damage of Engelbreth-Holm-Swarm matrix. Am J Pathol 1997; 151: 215-231. (Pubitemid 27283973)
6. Rao RK, Baker RD, Baker SS, Gupta A, Holycross M. Oxidant-induced disruption of the intestinal epithelial barrier function: role of protein tyrosine phosphorylation. Am J Physiol 1997; 273: G812-G823.
7. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 1997; 10: 485-494. (Pubitemid 27217204)
8. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424. (Pubitemid 46217686)
9. Szabó C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007; 6: 662-680. (Pubitemid 47207751)
10. Kong SK, Yim MB, Stadtman ER, Chock PB. Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism: lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc2(6-20)NH2 peptide. Proc Natl Acad Sci USA 1996; 93: 3377-3382.
11. MacMillan-Crow LA, Greendorfer JS, Vickers SM, Thompson JA. Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys 2000; 377: 350-356.
12. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007; 75: 291-302. (Pubitemid 46961930)
13. Henle ES, Linn S. Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem 1997; 272: 19095-19098. (Pubitemid 27337692)
14. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-519. (Pubitemid 27053665)
15. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 2002; 32: 1102-1115. (Pubitemid 34603348)
16. Wanrooij S, Goffart S, Pohjoismäki JL, Yasukawa T, Spelbrink JN. Expression of catalytic mutants of the mtDNA helicase Twinkle and polymerase POLG causes distinct replication stalling phenotypes. Nucleic Acids Res 2007; 35: 3238-3251. (Pubitemid 47073590)
17. Lieber MR, Karanjawala ZE. Ageing, repetitive genomes and DNA damage. Nat Rev Mol Cell Biol 2004; 5: 69-75. (Pubitemid 38089843)
18. Rumley AG, Paterson JR. Analytical aspects of antioxidants and free radical activity in clinical biochemistry. Ann Clin Biochem 1998; 35: 181-200. (Pubitemid 28127548)
19. Keshavarzian A, Sedghi S, Kanofsky J, and et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1992; 103: 177-185.
20. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992; 103: 186-196.
21. Sedghi S, Fields JZ, Klamut M, and et al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut 1993; 34: 1191-1197. (Pubitemid 23274538)
22. Naito Y, Takagi T, Yoshikawa T. Neutrophil-dependent oxidative stress in ulcerative colitis. J Clin Biochem Nutr 2007; 41: 18-26. (Pubitemid 47266169)
23. Boughton-Smith NK, Evans SM, Hawkey CJ, and et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993; 342: 338-340. (Pubitemid 23227564)
24. Godkin AJ, De Belder AJ, Villa L, and et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996; 26: 867-872. (Pubitemid 26343776)
25. Singer II, Kawka DW, Scott S, and et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111: 871-885. (Pubitemid 26327590)
26. Sasaki M, Joh T. Oxidative stress and ischemia-reperfusion injury in gastrointestinal tract and antioxidant, protective agents. J Clin Biochem Nutr 2007; 40: 1-12. (Pubitemid 46449682)
27. Kokura S, Wolf RE, Yoshikawa T, Granger DN, Aw TY. Molecular mechanisms of neutrophil-endothelial cell adhesion induced by redox imbalance. Circ Res 1999; 84: 516-524. (Pubitemid 29138588)
28. Yoshida N, Yamaguchi T, Nakagawa S, Nakamura Y, Naito Y, Yoshikawa T. Role of P-selectin and intercellular adhesion molecule-1 in TNB-induced colitis in rats. Digestion 2001; 63: 81-86. (Pubitemid 32098446)
29. Nishimura T, Andoh A, Hashimoto T, Kobori A, Tsujikawa T, Fujiyama Y. Cellobiose prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. J Clin Biochem Nutr 2010; 46: 105-110.
30. Berlin C, Berg EL, Briskin MJ, and et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-195.
31. Nakamura S, Ohtani H, Watanabe Y, and et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993; 69: 77-85.
32. Schürmann GM, Bishop AE, Facer P, and et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36: 411-418.
33. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 1993; 363: 461-464. (Pubitemid 23179394)
34. Holzmann B, Weissman IL. Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-like alpha chain associated with either of two integrin beta chains, one of which is novel. EMBO J 1989; 8: 1735-1741. (Pubitemid 19273989)
35. Neuhaus H, Hu MC, Hemler ME, Takada Y, Holzmann B, Weissman IL. Cloning and expression of cDNAs for the alpha subunit of the murine lymphocyte-Peyer's patch adhesion molecule. J Cell Biol 1991; 115: 1149-1158. (Pubitemid 21909961)
36. Issekutz TB. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo. J Immunol 1991; 147: 4178-4184.
37. Yuan QA, Jiang WM, Krissansen GW, Watson JD. Cloning and sequence analysis of a novel beta 2-related integrin transcript from T lymphocytes: homology of integrin cysteine-rich repeats to domain III of laminin B chains. Int Immunol 1990; 2: 1097-1108. (Pubitemid 20376763)
38. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing. Proc Natl Acad Sci USA 1992; 89: 8254-8258.
39. Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994; 153: 517-528. (Pubitemid 24206281)
40. Viney JL, Jones S, Chiu HH, and et al. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol 1996; 157: 2488-2497. (Pubitemid 126450461)
41. Briskin M, Winsor-Hines D, Shyjan A, and et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110. (Pubitemid 27283962)
42. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856-863.
43. Takeuchi M, Baichwal VR. Induction of the gene encoding mucosal vascular addressin cell adhesion molecule 1 by tumor necrosis factor alpha is mediated by NF-kappa B proteins. Proc Natl Acad Sci USA 1995; 92: 3561-3565.
44. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
45. Oshima T, Pavlick KP, Laroux FS, and et al. Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am J Physiol Cell Physiol 2001; 281: C1096-C1105.
46. Ando T, Jordan P, Wang Y, and et al. MAdCAM-1 expression and regulation in murine colonic endothelial cells in vitro. Inflamm Bowel Dis 2005; 11: 258-264. (Pubitemid 40439680)
47. Sasaki M, Elrod JW, Jordan P, and et al. CYP450 dietary inhibitors attenuate TNF-alpha-stimulated endothelial molecule expression and leukocyte adhesion. Am J Physiol Cell Physiol 2004; 286: C931-C939. (Pubitemid 38543822)
48. Mizushima T, Sasaki M, Ando T, and et al. Blockage of angiotensin II type 1 receptor regulates TNF-alpha-induced MAdCAM-1 expression via inhibition of NF-kappaB translocation to the nucleus and ameliorates colitis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G255-G266.
49. Katada K, Yoshida N, Suzuki T, and et al. Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice. Inflamm Res 2008; 57: 84-91. (Pubitemid 351302060)
50. Sasaki M, Jordan P, Welbourne T, and et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol 2005; 5: 3.
51. Hanauer SB, Feagan BG, Lichtenstein GR, and et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549. (Pubitemid 34621118)
52. Sands BE, Anderson FH, Bernstein CN, and et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885. (Pubitemid 38252535)
53. Rutgeerts P, Sandborn WJ, Feagan BG, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
54. Hanauer SB, Sandborn WJ, Rutgeerts P, and et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
55. Sandborn WJ, Hanauer SB, Rutgeerts P, and et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. (Pubitemid 47300424)
56. Sandborn WJ, Feagan BG, Stoinov S, and et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238. (Pubitemid 47080387)
57. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-76. (Pubitemid 36005801)
58. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008; 10: 393-406.
59. Reinisch W, Hommes DW, Van Assche G. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1138-1144. (Pubitemid 44085682)
60. Ito H, Takazoe M, Fukuda Y, and et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-996. (Pubitemid 38451170)
61. Sandborn WJ, Feagan BG, Fedorak RN, and et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
62. Krieglstein CF, Cerwinka WH, Sprague AG, and et al. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 2002; 110: 1773-1782. (Pubitemid 36076484)
63. Takazoe M, Watanabe M, Kawaguchi T, and et al. Oral alpha-4 integrin Inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136 Suppl 1: 1240.
64. Sandborn WJ, Colombel JF, Enns R, and et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. (Pubitemid 41565956)
65. Feagan BG, Greenberg GR, Wild G, and et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-2507. (Pubitemid 41007865)
66. Feagan BG, Greenberg GR, Wild G, and et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-1377.
67. Rijcken EM, Laukoetter MG, Anthoni C, and et al. Immunoblockade of PSGL-1 attenuates established experimental murine colitis by reduction of leukocyte rolling. Am J Physiol Gastrointest Liver Physiol 2004; 287: G115-G124. (Pubitemid 38802125)
68. Taniguchi T, Tsukada H, Nakamura H, and et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 1998; 13: 945-949. (Pubitemid 28448968)
69. Soriano A, Salas A, Sans M, and et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000; 80: 1541-1551.